目的 观察益肾通胶囊(YST)对小鼠前列腺炎及前列腺增生组织学变化的影响。方法 雄性KM小鼠随机分为7组，即正常对照组(Normal)、前列腺炎组(CNP)、前列腺增生组(BPH)、前列腺炎合并前列腺增生组(CNP+BPH)、前列腺炎干预组(CNP-YST)、前列腺增生干预组(BPH-YST)、前列腺炎合并前列腺增生干预组(CNP+BPH-YST)。除正常对照组外，其余各组动物分别按照相应的造模方法复制模型。各干预组每天均灌胃给予益肾通(1.0 g·kg-1)，正常对照组、模型组同时予等容积蒸馏水灌胃。于第28天全部断颈处死小鼠，取其前列腺组织行病理学检查，采用免疫组化法检测各组小鼠前列腺组织IL8、Ki67抗原表达。结果 CNP+BPH组Ki67-LI(73.20±5.94)高于BPH组(51.20±4.20)，差异有统计学意义(P ＜ 0.01)；CNP-YST组IL8-LI(13.90±1.91)低于CNP组(44.10±3.67)，差异有统计学意义(P ＜ 0.01)；BPH-YST组IL8-LI(18.07±2.05)与BPH组(21.60±2.07)比较，差异无统计学意义(P ＞ 0.01)；CNP+BPH-YST组IL8-LI(15.90±2.56)低于CNP+BPH组(54.20±3.29)，差异有统计学意义(P ＜ 0.01)。结论 益肾通胶囊可抑制前列腺组织学炎性改变，进而抑制前列腺增生的发生。

Objective To observe the effect of Yishentong Capsules(YC) on the histological changes of prostate gland in prostatitis and prostate hyperplasia. Methods Seventy male KM mice were randomly divided into normal control group，chronic nonbacterial prostatitis group(CNP)，benign prostatic hyperplasia group(BPH)，prostatitis with prostatic hyperplasia group(CNP+BPH)，prostatitis YC intervention group(CNP-YC)，benign prostatic hyperplasia YC intervention group(BPH-YC)，prostatitis with benign prostatic hyperplasia YC intervention group(CNP+ BPH-YC). Except for the normal control group，mice in the other groups were modeled in accordance with the corresponding modeling method. The intervention groups were treated with YC at 1.0 g/kg by intragastric administration，and the same volume of distilled water was given to the mice in normal control group and model groups. On day 28，all of the mice were executed，the pathological changes of prostate gland were observed，and prostate IL-8 and Ki67 expression levels were also detected by immunohistochemical assay. Results The Ki67-LI in CNP+BPH group(73.20±5.94) was higher than that in BPH group(51.20±4.20)，and the IL-8-LI in CNP-YC group(13.90±1.91) was lower than that in CNP group(44.10±3.67)，the difference being significant(P < 0.01). CNP+BPH-YC group had lower IL-8-LI level(15.90±2.56) than CNP+BPH group(54.20±3.29)，the difference being significant(P < 0.01). Conclusion Yishentong Capsules can reduce the incidence of benign prostatic hyperplasia by relieving the inflammatory changes in prostate gland.

R285.5

广东省科技计划项目(粤科函社字[2010]1096第131号)。